RPR manufacture of Forest's Levothroid lacked adequate stability data -- FDA warning letter.
Executive Summary
RPR LEVOTHROID STABILITY TESTING PROCEDURES CITED IN WARNING LETTER sent to the company by FDA's San Juan, P.R. district office. Rhone-Poulenc Rorer has "failed to generate adequate stability data to support the 24-month expiration date assigned to...lots of Levothroid 88 mcg, 112 mcg and 137 mcg tablets manufactured and distributed [by Forest Labs] during 1993 and 1994," FDA said in its Nov. 4 warning letter. "The expiration date was not based on data from an adequate number of batches, it was based on accelerated data from a single batch of each strength," FDA charged.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth